No argument and no need for discussion. You don't seem the type to emotionally hammer incessantly, so just to clarify my opinions:
(1) no question that dilution is behind BIEL, it is not, and I believe whoever suggested that was, at the time, merely being hopeful, although ill-informed; I would say dilution has lessened significantly, as compared to previous years, when sales were far less than they are now;
(2) The foreseeable future is interesting, and sort of refers back to (1) in that no one knows its length or whether it is behind the company or not; yesterday there was dilution, in my opinion, and I have known of it for years and I have supported it. Do I like it? No, only a moron would do so. Is it better than being ground down by debt and debt service? Yes;
(3) BIEL is not debt free;
(4) My opinion is that BIEL will run strongly when progress is achieved, I've written about it a number of times, given my opinions as to projections and expect to do well by BIEL; and
(5) More than 140 million Americans are suffering from chronic and acute pain today and cannot legally acquire BIEL's ActiPatch OTC here in the USA, while more than a Billion people in 50 countries can acquire it OTC today! That is a shameful, outrageous travesty, when one considers >1Million devices used, >3/4Billion treatment hours and not one negative side-effect, ever! I try to look at, or for, the bright side of things to get a balanced view. So, turning the telescope around, rather than being outraged, which the American people should be, to me, that means >3/4 Billion pain management treatment hours that were partially, or fully, drug-free! There is no reason why users can't reduce drug intake while ramping up on ActiPatch, in order to find the right ratio, or a total cessation of drugs as most have to no drugs at all because everyone is different. For me, it is the reduction of drug use that is the benefit. Physical side-effects and analgesic drug dependency are just one of the issues threatening us, it is sometimes discouraging that we have a major solution stuck in regulatory gridlock and few with the courage to demand immediate resolution. . . . or soon
